Recombinant Human VEGF-Ax Protein

Name: Recombinant Human VEGF-Ax Protein
Brand: R&D Systems
SKU: 9018-VE
Price: 421 USD
Availability: InStock

R&D Systems | Catalog # 9018-VE

Submit a review

Product Documents

VEGF 165 Extended Isoform

100% Guarantee

Product Specifications
Preparation & Storage
Calculators
Background
Product Documents
Specific Notices
Research Areas
Related Blogs

Key Product Details

R&D Systems CHO-derived Recombinant Human VEGF-Ax Protein (9018-VE)
Quality control testing to verify active proteins with lot specific assays by in-house scientists
All R&D Systems proteins are covered with a 100% guarantee

Source

CHO

Accession Number

NP_001303939

Structure / Form

Disulfide-linked homodimer

Applications

Bioactivity

View all VEGF Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human VEGF protein

Human VEGF-A (Ala27-Arg191) Accession # NP_001303939	SAGQEEGASLRVSGTRSLTRKD
N-terminus		C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala27

Predicted Molecular Mass

21 kDa

SDS-PAGE

22-29 kDa, reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Human VEGF R2/KDR/Flk‑1 Fc Chimera (Catalog # 357-KD) is immobilized at 0.5 µg/mL (100 µL/well), the concentration of Recombinant Human VEGF-Ax that produces 50% of the optimal binding response is approximately 1-6 ng/mL.
Recombinant Human VEGF-Ax weakly binds to Recombinant Human Neuropilin‑1 (Catalog # 3870-N1).

Formulation, Preparation, and Storage

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: 9018-VE

Formulation	Lyophilized from a 0.2 μm filtered solution in HCl with BSA as a carrier protein.
Reconstitution	Reconstitute at 250 μg/mL in 4 mM HCl.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Carrier Free: 9018-VE/CF

Formulation	Lyophilized from a 0.2 μm filtered solution in HCl.
Reconstitution	Reconstitute at 250 μg/mL in 4 mM HCl.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: VEGF

Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult (1, 2). It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues and a cystine knot structure (3). Humans express two sets of alternatively spliced isoforms of 121, 145, 165, 183, 189, and 206 amino acids (aa) in length (3, 4). Isoforms other than VEGF₁₂₁ contain basic heparin-binding regions and are not freely diffusible (3, 4). VEGF₁₆₅ appears to be the most abundant and potent of the angiogenic isoform set, followed by VEGF₁₂₁ and VEGF₁₈₉ (3, 5). The anti-angiogenic or “b” set of isoforms is differentially spliced to contain six alternative amino acids at the C-terminus, and are the more highly expressed isoforms in normal adult tissue (6). VEGF_165b, like VEGF₁₂₁ but unlike most angiogenic isoforms, does not bind heparins and is therefore diffusible (3). Human VEGF₁₆₅ shares 88% aa sequence identity with corresponding regions of mouse and rat, 96% with porcine, 95% with canine, and 93% with feline, equine and bovine VEGF₁₆₅, respectively. In addition to alternatively spliced VEGF isoforms, multiple fragments of VEGF can be generated by extracellular proteolysis (4). VEGFs bind the type I transmembrane receptor tyrosine kinases VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR) on endothelial cells (3). Although VEGF affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity (3, 5). VEGF₁₆₅ binds the semaphorin receptor, Neuropilin-1 and promotes complex formation with VEGF R2 (7). An extended form of VEGF-A, known as VEGF-Ax, results from the C-terminal addition of 22 amino acids (8). VEGF-Ax is produced by vascular endothelial cells, retains the ability to bind VEGF R2 but not Neuropilin-1, and functions as an anti-angiogenic protein (8). VEGF is required during embryogenesis to regulate the proliferation, migration, and survival of endothelial cells (3, 5). In adults, VEGF functions mainly in wound healing and the female reproductive cycle (5). Pathologically, it is involved in tumor development and tumor vascular leakage (9). Circulating VEGF levels correlate with disease activity in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus (10). VEGF is induced by hypoxia and cytokines such as IL-1, IL-6, IL-8, Oncostatin M, and TNF-alpha (5, 11).